NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)

The National Institutes of Health (NIH) is seeking applications for the Small Business Innovation Research (SBIR) Phase IIB Small Market Awards to support the commercialization of technologies for heart, lung, blood, and sleep disorders and diseases. The goal of this program is to facilitate the commercialization of technologies developed by small business concerns (SBCs) and to promote partnerships between SBCs and third-party investors and/or strategic partners. • The program is specifically designed to support products that address rare diseases or products targeted at young pediatric populations. • Applications must have previously been funded by SBIR or STTR Phase II awards and must require eventual Federal regulatory approval/clearance. • Competitive preference and funding priority will be given to applications deemed likely to result in a clinically-relevant commercial product. • The program will utilize the R44 activity code and will have an estimated funding amount of $21,000,000, with an award ceiling of $3,500,000.